<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004342</url>
  </required_header>
  <id_info>
    <org_study_id>199/11901</org_study_id>
    <secondary_id>UW-730</secondary_id>
    <nct_id>NCT00004342</nct_id>
  </id_info>
  <brief_title>International Registry for Severe Chronic Neutropenia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Document the clinical course of severe chronic neutropenia (SCN).&#xD;
&#xD;
      II. Monitor and assess long term safety of primary treatment in SCN patients in the United&#xD;
      States, Canada, Europe, and Australia.&#xD;
&#xD;
      III. Study the incidence and outcome of adverse events such as osteoporosis, splenomegaly,&#xD;
      cytogenetic abnormalities, myelodysplastic syndrome, and leukemia.&#xD;
&#xD;
      IV. Evaluate growth and development and hematologic parameters. V. Monitor for clinically&#xD;
      significant changes in primary treatment response over time.&#xD;
&#xD;
      VI. Establish a physician network to increase the understanding of SCN. VII. Establish a&#xD;
      demographic database to allow for future research.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      Patients are treated by the referring physician as medically indicated. Clinical data are&#xD;
      collected at baseline and then every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1994</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Adult Neutropenic Subject</arm_group_label>
    <description>Adult subjects with diagnosis of severe chronic neutropenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minor Neutropenic Subject</arm_group_label>
    <description>Children under 18 years of age who are diagnosed with severe chronic neutropenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parent of Minor Neutropenic Subjects</arm_group_label>
    <description>Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Bone marrow, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed with severe chronic neutropenia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria - Subjects are eligible for enrollment if they meet the following&#xD;
        criteria:&#xD;
&#xD;
          1. A confirmed diagnosis of severe chronic neutropenia based on documented absolute&#xD;
             neutrophil counts of less than 0.5x109/L on at least three occasions in the three&#xD;
             months prior to enrollment.&#xD;
&#xD;
          2. For subjects with presumed cyclic neutropenia, documentation of at least two&#xD;
             neutrophil cycles is preferred. Documentation should include the nadirs with&#xD;
             neutrophil counts of less than 200 followed by a clear increase in the counts&#xD;
             generally to at least 500 to 1000 followed by a second nadir, usually expected to&#xD;
             occur at about three weeks after the first nadir, i.e., cycling with a three week&#xD;
             periodicity. Documentation with at least six weeks of counts and two expected nadirs&#xD;
             is preferred.&#xD;
&#xD;
             Cases not showing clear oscillations will be categorized as congenital (if neutropenia&#xD;
             or neutropenic complications appear to have occurred from birth) or idiopathic (if all&#xD;
             symptoms in evidence point to an acquired disorder occurring after the first year of&#xD;
             life).&#xD;
&#xD;
          3. Bone marrow aspiration consistent with the diagnosis of congenital, cyclic or&#xD;
             idiopathic neutropenia. In all of these conditions, it is expected that the marrow&#xD;
             aspirate evaluation at the time of neutropenia will show a deficiency of mature&#xD;
             neutrophils. An exception is myelokathexis, a condition with large accumulations of&#xD;
             neutrophils with pycnotic nuclei in the marrow. Bone marrow aspirates may show some&#xD;
             dyspoiesis of the neutrophil lineage, but abnormalities of erythropoiesis or platelet&#xD;
             formation are, in general, inconsistent with the diagnosis of SCN.&#xD;
&#xD;
          4. Normal cytogenetic evaluation. The only exception being cases of well documented&#xD;
             severe congenital neutropenia with preferably previously documented normal cytogenetic&#xD;
             evaluation will now be enrolled in the Registry at the time of evolution to leukemia.&#xD;
&#xD;
          5. History of recurrent infections (i.e., severe mouth ulcers, gingivitis and sinusitis).&#xD;
&#xD;
          6. Age greater than three months.&#xD;
&#xD;
          7. Independent of hematological parameters, subjects with the following diagnoses may be&#xD;
             included: Shwachman-Diamond syndrome (SDS), glycogen storage disease type 1b (GSD1b),&#xD;
             Barth syndrome, and Cohen's syndrome.&#xD;
&#xD;
          8. Subjects with moderately severe chronic neutropenia (i.e., ANC less than 1.0x109/L)&#xD;
             and recurrent severe infections (i.e., deep tissue infections of subcutaneous areas,&#xD;
             lungs, liver, etc.).&#xD;
&#xD;
          9. Immune neutropenia with positive anti-neutrophil antibodies meeting criteria in 1, 3,&#xD;
             5 and 6.&#xD;
&#xD;
         10. All SCN subjects originally enrolled in Amgen-sponsored SCN studies.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Neutropenia known to be drug induced&#xD;
&#xD;
          2. Primary myelodysplasia&#xD;
&#xD;
          3. Primary leukemia&#xD;
&#xD;
          4. Aplastic anemia&#xD;
&#xD;
          5. Known HIV disease&#xD;
&#xD;
          6. Systemic autoimmune diseases such as rheumatoid arthritis or systemic lupus&#xD;
             erythematosus&#xD;
&#xD;
          7. Chemotherapy-induced neutropenia (within the last 5 years)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Chandler Dale</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Boston ChildrenÂ¹s Cancer and Blood Disorders Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akiko Shimamura, MD, PhD</last_name>
      <phone>617-919-6109</phone>
      <email>Akiko.Shimamura@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Newburger, MD</last_name>
      <phone>508-856-4225</phone>
      <email>Peter.Newburger@umassmed.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly J. Walkovich, MD</last_name>
      <phone>734-647-2893</phone>
      <email>kwalkovi@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Children's Hospital</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Bonilla</last_name>
      <phone>973-754-3230</phone>
      <email>bonillam@sjhmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Caterna Lovaglio, RN/CRA</last_name>
      <phone>973-754-3778</phone>
      <email>lovaglic@sjhmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Chandler Dale</last_name>
      <phone>206-543-7215</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Leischke, PhD</last_name>
      <phone>+61 3 9902 9720</phone>
      <email>Graham.Lieschke@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CancerCare Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Paula Cham</last_name>
      <phone>204-787-4147</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yigal Dror, MD</last_name>
      <phone>+416-813-5630</phone>
      <email>yigal.dror@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Philippa McCaffrey</last_name>
      <phone>+416-813-8886</phone>
      <email>phillippa.mccaffrey@sickkids.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Zeidler, Dr.med</last_name>
      <phone>+49-511-532-6710</phone>
      <email>zeidler.cornelia@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Sonja Klein</last_name>
      <email>Klein.Sonja@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals, Yorkshire Regional Centre for Paediatric Oncology &amp; Haematology</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Kinsey, MD</last_name>
      <phone>+44-113-392-8191</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Dale DC, Bonilla MA, Boxer L, et al.: Development of AML/MDS in a subset of patients (PTS) with severe chronic neutropenia (SCN). Blood 84(10 suppl 1): 518a, 1994.</citation>
  </reference>
  <reference>
    <citation>Guerra J, Withers DA, Boxer LM. Myb binding sites mediate negative regulation of c-myb expression in T-cell lines. Blood. 1995 Sep 1;86(5):1873-80.</citation>
    <PMID>7655015</PMID>
  </reference>
  <reference>
    <citation>Welte K, Dale D. Pathophysiology and treatment of severe chronic neutropenia. Ann Hematol. 1996 Apr;72(4):158-65. doi: 10.1007/s002770050156.</citation>
    <PMID>8624368</PMID>
  </reference>
  <reference>
    <citation>Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, Olson K, Paderanga D, Shannon K. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995 Dec 15;86(12):4579-86.</citation>
    <PMID>8541548</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>David Chandler Dale</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>chronic neutropenia</keyword>
  <keyword>disease-related problem/condition</keyword>
  <keyword>hematologic disorders</keyword>
  <keyword>neutropenia</keyword>
  <keyword>rare disease</keyword>
  <keyword>severe chronic neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

